ISCHEMIA-CKD EXTEND: Invasive Strategy Does Not Improve Survival in CKD

Long-term data from the ISCHEMIA-CKD EXTEND trial show that an invasive strategy does not improve survival compared with conservative treatment in stable coronary artery disease and advanced chronic kidney disease, according to findings published by IT Boltwise.

  • Reducing systemic inflammation via the monoclonal antibody ziltivekimab successfully lowered inflammatory markers like hsCRP, but it failed to reduce major adverse cardiovascular events in clinical trials.
  • Biomarker discrepancies—such as creatinine- versus cystatin-C-based kidney filtration estimates—significantly alter risk stratification and should be monitored closely by clinicians.

Therapy planning for stable coronary artery disease alongside advanced chronic kidney disease often sparks tension between cardiology and nephrology. While stent implantations or bypass operations reduce angina pectoris symptoms in the short term, long-term impacts on hard endpoints like death remain uncertain.

After a median follow-up period of 8 years, researchers recorded 429 total deaths, accounting for 55 percent of the cohort. Overall mortality showed no statistically significant difference, with 57.4 percent in the invasive arm versus 56.8 percent in the conservative arm, yielding an adjusted hazard ratio of 1.05 and a 95 percent confidence interval from 0.87 to 1.28.

Cardiovascular mortality remained similarly balanced at 40.3 percent versus 38.4 percent, with a hazard ratio of 1.06 and a 95 percent confidence interval from 0.84 to 1.34. Restricted mean survival time tracked closely at 1,941 days versus 1,990 days, resulting in an adjusted difference of minus 99 days.

In that larger cohort, mortality rates also remained tightly clustered at 26 percent in the invasive arm compared to 27 percent in the conservative arm after confirming vital status for 96 percent of participants and logging 1,071 deaths, it boltwise reported. Methodological limitations in the extended follow-up included a lack of systematic tracking for non-fatal infarctions, repeat procedures, and individual quality-of-life metrics.

Trial Arm Participant Count Overall Mortality (%) Cardiovascular Mortality (%)
Invasive Strategy 388 57.4% 40.3%
Conservative Treatment 389 56.8% 38.4%

Drug-based risk reduction strategies in chronic kidney disease target vascular inflammation, which frequently accelerates atherosclerosis in this patient population. After a median duration of 33 months, the trial showed no reduction in major adverse cardiovascular events—encompassing cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke—with 17.6 percent under active treatment versus 17.7 percent under placebo, yielding a hazard ratio of 0.99.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Dale Utvikling Finds Three Pianos and Waste Dumped on Property in Sandnes

JP Morgan Forecasts Argentina Inflation to Hover Near 2% by 2027 Elections